Josh Ginsburg
Biotech, gold, insider ownership, natural resources

The Green Light Is On For Soligenix

Soligenix (SNGX.OB) is an up and coming biotech company with a large pipeline focusing on bio-therapeutic pharmaceuticals as well as bioterrorist/bio-warfare vaccines and treatments. In my last article on Soligenix we took a look at the company's current product pipeline and near-term catalysts. Since then SNGX has been picked up by Zack's Investment research and issued a "Buy" with a $4.50 price target over the next 1-3 months. As well the company has secured a new $7.1M in capital and is continuing to push full force ahead into new 2013/2014 catalysts. In this article we will take a look at the current upcoming trial milestones, partnerships and insider activity, which could be signaling investors to take a...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details